NYSE ARCA | ETF
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the index), the fund employs a sampling strategy.
It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index.
The index represents the pharmaceuticals segment of the S&P Total Market Index (S&P TMI).
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| LBPH | Longboard Pharmaceuticals Inc | Healthcare | Biotechnology | 4.19% |
| CTLT | Catalent Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 3.98% |
| ITCI | Intracellular Th | Healthcare | Drug Manufacturers - Specialty & Generic | 3.74% |
| CBAY | Cymabay Therapeu | Healthcare | Biotechnology | 3.73% |
| LQDA | Liquidia Technologies Inc | Healthcare | Biotechnology | 2.40% |
| AXSM | Axsome Therapeutics Inc | Healthcare | Biotechnology | 2.32% |
| OGN | Organon & Co | Healthcare | Drug Manufacturers - General | 2.31% |
| MBX | MBX Biosciences, Inc. Common Stock | Healthcare | Biotechnology | 2.31% |
| EWTX | Edgewise Therapeutics Inc | Healthcare | Biotechnology | 2.28% |
| ELAN | Elanco Animal Health | Healthcare | Drug Manufacturers - Specialty & Generic | 2.13% |
| AMRX | Amneal Pharmaceuticals, Inc. Class A Common Stock | Healthcare | Drug Manufacturers - Specialty & Generic | 2.09% |
| VTRS | Viatris Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 2.09% |
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 2.04% |
| CRNX | Crinetics Pharmaceuticals Inc | Healthcare | Biotechnology | 2.03% |
| MNMD | Mind Medicine Inc | Healthcare | Biotechnology | 2.01% |
| JNJ | Johnson & Johnson | Healthcare | Drug Manufacturers - General | 2.00% |
| BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 2.00% |
| XERS | Xeris Pharmaceuticals Inc | Healthcare | Biotechnology | 2.00% |
| SUPN | Supernus Pharmaceuticals Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 1.98% |
| RPRX | Royalty Pharma Plc | Healthcare | Biotechnology | 1.96% |